Immune checkpoint inhibition for pediatric patients with recurrent/refractory CNS tumors: a single institution experience
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Immune checkpoint inhibition for pediatric patients with recurrent/refractory CNS tumors: a single institution experience
Authors
Keywords
-
Journal
JOURNAL OF NEURO-ONCOLOGY
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-07-05
DOI
10.1007/s11060-020-03578-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1–2 trial
- (2020) Kara L Davis et al. LANCET ONCOLOGY
- Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma
- (2019) Timothy F. Cloughesy et al. NATURE MEDICINE
- Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study
- (2019) Caroline Robert et al. LANCET ONCOLOGY
- Tumor mutation burden: from comprehensive mutational screening to the clinic
- (2019) Francesca Galuppini et al. Cancer Cell International
- Towards Immunotherapy for Pediatric Brain Tumors
- (2019) Stacie Shiqi Wang et al. TRENDS IN IMMUNOLOGY
- P14.47 Tissue immune markers for central nervous system germinoma
- (2019) A K CHAN et al. NEURO-ONCOLOGY
- Incidence rates of immune-related adverse events and their correlation with response in advanced solid tumours treated with NIVO or NIVO+IPI: a systematic review and meta-analysis
- (2019) Puyuan Xing et al. Journal for ImmunoTherapy of Cancer
- Progress and challenges of predictive biomarkers of anti PD-1/PD-L1 immunotherapy: A systematic review
- (2018) Feifei Teng et al. CANCER LETTERS
- Tumor Mutation Burden: Leading Immunotherapy to the Era of Precision Medicine?
- (2018) Conor E. Steuer et al. JOURNAL OF CLINICAL ONCOLOGY
- PD-1/PD-L1 and immune-related gene expression pattern in pediatric malignant brain tumors: clinical correlation with survival data in Korean population
- (2018) Kihwan Hwang et al. JOURNAL OF NEURO-ONCOLOGY
- Central Nervous System Germinomas Express Programmed Death Ligand 1
- (2018) Miriam E Wildeman et al. JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY
- International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study
- (2018) Franck Pagès et al. LANCET
- IMMU-09. OUTCOME OF PATIENTS WITH RECURRENT DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) TREATED WITH PEMBROLIZUMAB (ANTI-PD-1): A PEDIATRIC BRAIN TUMOR CONSORTIUM STUDY (PBTC045)
- (2018) Eugene Hwang et al. NEURO-ONCOLOGY
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
- (2018) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1/PD-L1 expression in a series of intracranial germinoma and its association with Foxp3+ and CD8+ infiltrating lymphocytes
- (2018) Bin Liu et al. PLoS One
- Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non–Small-Cell Lung Cancer
- (2018) Koji Haratani et al. JAMA Oncology
- Nivolumab in the Treatment of Recurrent or Refractory Pediatric Brain Tumors
- (2018) Hamza S. Gorsi et al. JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY
- Tumor-infiltrating T cells and PD-L1 expression in childhood malignant extracranial germ-cell tumors
- (2018) Renata Boldrini et al. OncoImmunology
- Survival outcomes in pediatric recurrent high-grade glioma: results of a 20-year systematic review and meta-analysis
- (2017) Cassie Kline et al. JOURNAL OF NEURO-ONCOLOGY
- Recurrent glioma clinical trial, CheckMate-143: the game is not over yet
- (2017) Anna C. Filley et al. Oncotarget
- Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy
- (2016) J. M. Pitt et al. ANNALS OF ONCOLOGY
- Management of toxicities of immune checkpoint inhibitors
- (2016) Lavinia Spain et al. CANCER TREATMENT REVIEWS
- Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency
- (2016) Eric Bouffet et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab: first experience with recurrent primary central nervous system (CNS) tumors
- (2016) Deborah T. Blumenthal et al. JOURNAL OF NEURO-ONCOLOGY
- Relapse patterns and outcome after relapse in standard risk medulloblastoma: a report from the HIT-SIOP-PNET4 study
- (2016) Magnus Sabel et al. JOURNAL OF NEURO-ONCOLOGY
- Programmed cell death ligand-1 (PD-L1) expression by immunohistochemistry: could it be predictive and/or prognostic in non-small cell lung cancer?
- (2016) Mari Mino-Kenudson et al. Cancer Biology & Medicine
- Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes
- (2015) M. Freeman-Keller et al. CLINICAL CANCER RESEARCH
- Phase I Clinical Trial of Ipilimumab in Pediatric Patients with Advanced Solid Tumors
- (2015) M. S. Merchant et al. CLINICAL CANCER RESEARCH
- Immunotherapy response assessment in neuro-oncology: a report of the RANO working group
- (2015) Hideho Okada et al. LANCET ONCOLOGY
- Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
- (2015) Jeffrey S Weber et al. LANCET ONCOLOGY
- Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial
- (2015) Alexander M M Eggermont et al. LANCET ONCOLOGY
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
- (2015) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- The odds of immunotherapy success
- (2015) M. M. Gubin et al. SCIENCE
- In Situ Tumor PD-L1 mRNA Expression Is Associated with Increased TILs and Better Outcome in Breast Carcinomas
- (2014) K. A. Schalper et al. CLINICAL CANCER RESEARCH
- Clinical impact of programmed cell death ligand 1 expression in colorectal cancer
- (2013) Raoul A. Droeser et al. EUROPEAN JOURNAL OF CANCER
- Ipilimumab: A novel immunostimulatory monoclonal antibody for the treatment of cancer
- (2011) Grazia Graziani et al. PHARMACOLOGICAL RESEARCH
- The Microenvironment of Germ Cell Tumors Harbors a Prominent Antigen-Driven Humoral Response
- (2009) S. N. Willis et al. JOURNAL OF IMMUNOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More